|Day Low/High||226.16 / 229.93|
|52 Wk Low/High||177.05 / 264.97|
How September markets digest August ahead of momentous events will be far more important to uptrend maintenance than how August closed.
Apple's weight in the (price-weighted) Dow Jones Industrial Average, effective this morning, will be reduced from 12% to 3% -- based on the company's 4-1 stock split. In response to that split, Amgen , Honeywell , and Salesforce are being added to t...
September, not October, is historically the weakest month of the year for equity markets, though October has had more high profile collapses.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Let's check the charts as this biotech replaces Pfizer on the DJIA.
Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
What I see: This stock responds well to economic recovery.
Monday's market action was in no way similar to that recent disparity between the 'haves' and 'have nots.'
Negotiations on the next round of stimulus, more so than tension between Washington and Beijing, and more so than earnings season, will control short-term financial market performance.
I like putting some of my money with incredibly successful folks who are well-connected and have a history of success.
The RMPIA rose 3.2% for May and 3.3% for the first five months of 2020.
Don't just follow the herd, time your exits and entrances well -- even if it is a big player like Warren Buffett that is leading the charge.
Market leadership may be lacking on Thursday despite rising trading volumes, plus an update on Apple, Microsoft, Mastercard, Amazon and Gilead.
Here's how to play the biotech with earnings on the horizon.
So far, earnings season has not been the obstacle that many have feared.
They buy and buy and buy. The same stocks. Over and over. No end to it.
RMPIA ended January up 0.8%, but now the damage from the Wuhan virus is weighing on the future.
It's no secret that the Fed would like to get out of the short-term repo business.
What I suggest individual investors do is give their portfolios a physical. Like a visit to the doctor.
This company made headlines in 2019, and I'm betting on it as a great play -- in many senses of the word -- for this new year.
Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.
AMGN appears to have taken a turn for the better and is now looking at targets of $254 and $270.
Now, many Real Money Post Industrial Average stocks should see a boost from the holiday splurge by shoppers.
Also, Fed Chairman Powell says there are no plans for a U.S. digital currency (for now), plus Tesla's electric pickup.
The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.